Assessment of KAN-101 in Celiac Disease (ACeD)

• Status: Active, not recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

A safety study of KAN-101 in patients with celiac disease. The study has two parts:

1. Part A - first in human study in which patients receive a single dose of KAN-101

2. Part B - patients will receive three doses of either KAN-101 or placebo

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

Criteria

Key Inclusion Criteria:

1. Adults aged 18 to 70 years inclusive

2. Diagnosed with celiac disease based on positive serology (eg, tissue transglutaminase IgA antibody and/or deamidated gliadin peptide IgG) and intestinal histology consistent with ≥ Marsh Type II or with evidence of villous atrophy

3. Has HLA-DQ2.5 genotype (HLA-DQA1*05 and HLA-DQB1*02) (homozygotes or heterozygotes)

4. Has followed a GFD for > 12 months immediately prior to study entry

5. Negative or weak positive for tTG-IgA and negative or weak positive for DGP-IgA/IgG during screening

6. Male or female. Females of childbearing potential must use at least 2 acceptable birth control methods

7. Capable of understanding and complying with protocol requirements

8. Patient understands and has signed the informed consent form

Key Exclusion Criteria:

1. Refractory celiac disease

2. Selective IgA deficiency

3. Positive for HLA-DQ8 (DQA1*03, DQB1*0302)

4. Previous treatment with tolerance-inducing therapies for celiac disease

5. Known wheat allergy

6. Part B only: History of hyperacute or prolonged symptoms following gluten exposure

7. Uncontrolled or significant medical conditions (including active infections or chronic hepatitis) which, in the opinion of the Investigator, preclude participation

8. History of dermatitis herpetiformis

9. Pregnant or breastfeeding